A flood-damaged Pfizer joint-venture plant in India that makes injectable chemotherapy may not resume supply until mid-to-late 2028.
Publication|Articles|March 18, 2026
- ONCOLOGY Vol 40, Issue 2
- Volume 40
- Issue 02
- Pages: 84-87
What Events Have Affected the Cost of Cancer Care?: Looking Back on 40 Years of Economics in Oncology
Author(s)Tim Cortese
In each decade since the launch of the journal ONCOLOGY, cancer care has evolved, and with it the finances and costs associated with these improving treatments.
Advertisement
Advertisement
In 1985, the direct health services costs of cancer care were $18.1 billion.1 In 2015, that number was approximately $183 billion.2 And by 2030, recent estimates suggest the number will be $246 billion. Between just those referenced costs, that totals almost $450 billion dollars without adjusting for inflation.
Related to this article
Israel approved nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with CIS, expanding access beyond the US, UK, EU, Saudi Arabia, and UAE.
At The Liver Meeting 2026, Ryosuke Tateishi, MD, PhD, discussed what the US and Japan can learn from each other to prevent liver cancer.
Posters at The Liver Meeting 2026 refined HCC risk stratification in hepatitis delta or after HCV cure and examined ICI liver injury in cirrhosis.
A dual bispecific regimen of pasritamig and JNJ-9401 reduced PSA by at least 50% in 73% of heavily pretreated patients with metastatic CRPC.
In pooled phase 1/2 data, the PD-1/VEGF bispecific antibody cesalatamig produced a 33% objective response rate in PD-(L)1–resistant/refractory NSCLC.
Results showed a 33% confirmed ORR and a 7.4-month median PFS with serabelisib and sapanisertib plus paclitaxel in advanced endometrioid endometrial cancer.
Psychiatrists explain where ketamine and esketamine show real promise for depression in patients with cancer and where caution is still needed.
Advertisement
Advertisement